Prevention and treatment of allergic and pseudo-allergic reactions, including reactions to the introduction of contrast agents, blood transfusions, diagnostic use of histamine. Secondary treatment (after intramuscular injection of 0.01 mg / kg adrenaline) in the event of anaphylactic or anaphylactoid shock and angioneurotic edema.
Composition and form of release
Tavegil is produced in solution for parenteral administration. The active ingredient of the agent is clemastine hydrofumarate.
Tavegil in solution for injection is used in the prevention and treatment of pseudo-allergic and allergic reactions, as well as reactions to blood transfusion, administration of a contrast agent or diagnostic use of histamine.
The drug can be used as part of secondary therapy (after the introduction of adrenaline at a dosage of 0.01 mg per kg) of angioedema and anaphylactic or anaphylactoid shock.
In addition, the drug is used in the treatment of pollinosis, urticaria of various origins, itchy dermatoses, acute and chronic eczema, drug allergies, contact dermatitis and insect bites.
Tavegil is not prescribed for patients undergoing treatment with monoamine oxidase inhibitors. In addition, the drug is not prescribed to patients with lesions of the lower respiratory system, bronchial asthma, intolerance to the components of the drug, severe glucose-galactose malabsorption syndrome, galactose intolerance and severe lactase deficiency. The drug is not used in the treatment of women at the lactation stage. The use of the drug in the form of a solution for parenteral administration is contraindicated for intra-arterial administration, during pregnancy and fructose intolerance. Tavegil in solution and syrup is not used in the treatment of children under one year old, and tablets are not used for children under 6 years old.
With caution, Tavegil is prescribed to patients who have been found to have a stenosing stomach ulcer, pyloroduodenal obstruction, benign prostatic hypertrophy, complicated by urinary retention, obstruction of the urinary bladder, hyperthyroidism, increased extratrigocular hypodermal pressure, arterial hypertension and arterial hypertension and arterial hypertension.
Application during pregnancy and lactation
Important contraindications for the appointment of Tavegil are pregnancy and lactation.
Method of administration and dosage
Tavegil in solution is used only for intravenous and intramuscular administration. The solution is injected intravenously slowly. Adult patients receive 2 mg of the drug twice a day. To prevent the occurrence of anaphylactic or a response to the administration of histamine, intravenous administration of 2 mg of the drug directly during the period of their possible occurrence is shown: in the treatment of children, the dose of the drug is calculated at the rate of 0.025 mg of the drug per 1 kg of the child’s body weight per day, divided into two injections.
Taking Tavegil in high doses is capable of both depressing and stimulating effects on the human central nervous system. Also, patients may experience dryness of the oral mucosa, fixed dilation of the pupils, rush of blood to the upper body, disruption of the digestive tract.
To eliminate the symptoms of poisoning, the patient is washed with an isotonic sodium chloride solution, saline laxatives are prescribed and symptomatic treatment is prescribed.
Taking Tavegil may be accompanied by the development of increased fatigue, drowsiness, sedation, fatigue, impaired coordination of movements, dizziness, tremors of the extremities, dyspeptic disorders, decreased appetite, nasal congestion, palpitations, visual impairment, tinnitus, increased urination, photosensitivity and anaphylactic shock.
Storage conditions and periods
Tavegil must be stored in a dark place, protected from children. The shelf life is 5 years.